{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T22:27:27Z","timestamp":1791239247321,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-82854-1","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T08:29:30Z","timestamp":1735374570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Development and external validation of an early prediction model to identify irresponsive patients and prognosis of UDCA treatment in primary biliary cholangitis"],"prefix":"10.1038","volume":"14","author":[{"given":"Huiling","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyu","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongtao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenlin","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengji","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"82854_CR1","doi-asserted-by":"crossref","unstructured":"Ludwig, J., Dickson, E.R & McDonald, G. S. Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch. A Pathol. Anat. Histol. 379 (1978).","DOI":"10.1007\/BF00432479"},{"key":"82854_CR2","doi-asserted-by":"crossref","unstructured":"Miller, J.  et al. Cell-mediated immunity to a human liver-specific antigen in patients with active chronic hepatitis and primary biliary cirrhosis. Lancet (London England) 2 (1972).","DOI":"10.1016\/S0140-6736(72)92904-2"},{"key":"82854_CR3","unstructured":"AMA production in. Primary biliary cirrhosis is promoted by the TLR9 ligand CpG and suppressed by potassium channel blockers. https:\/\/pubmed.ncbi.nlm.nih.gov\/17256753\/"},{"key":"82854_CR4","doi-asserted-by":"crossref","unstructured":"EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67 (2017).","DOI":"10.1016\/j.jhep.2017.03.022"},{"key":"82854_CR5","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/hep.30145","volume":"69","author":"KD Lindor","year":"2019","unstructured":"Lindor, K. D., Bowlus, C. L., Boyer, J., Levy, C. & Mayo, M. Primary biliary cholangitis: 2018 Practice Guidance from the American Association for the study of Liver diseases. Hepatology 69, 394\u2013419 (2019).","journal-title":"Hepatology"},{"key":"82854_CR6","unstructured":"Long-term impact. Of preventive UDCA therapy after transplantation for primary biliary cholangitis. https:\/\/pubmed.ncbi.nlm.nih.gov\/32275981\/"},{"key":"82854_CR7","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1053\/j.gastro.2009.01.003","volume":"136","author":"EMM Kuiper","year":"2009","unstructured":"Kuiper, E. M. M. et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 136, 1281\u20131287 (2009).","journal-title":"Gastroenterology"},{"key":"82854_CR8","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1002\/jgh3.12789","volume":"6","author":"N Kimura","year":"2022","unstructured":"Kimura, N. et al. Cumulative risk of developing a new symptom in patients with primary biliary cholangitis and its impact on prognosis. JGH Open. 6, 577\u2013586 (2022).","journal-title":"JGH Open."},{"key":"82854_CR9","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/s41395-018-0390-3","volume":"114","author":"ZM Younossi","year":"2019","unstructured":"Younossi, Z. M. et al. Diagnosis and management of primary biliary cholangitis. Am. J. Gastroenterol. 114, 48\u201363 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"82854_CR10","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1080\/14656566.2019.1601701","volume":"20","author":"AA Gossard","year":"2019","unstructured":"Gossard, A. A. & Lindor, K. D. Current and promising therapy for primary biliary cholangitis. Expert Opin. Pharmacother. 20, 1161\u20131167 (2019).","journal-title":"Expert Opin. Pharmacother"},{"key":"82854_CR11","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1016\/S0140-6736(24)01303-5","volume":"404","author":"A Tanaka","year":"2024","unstructured":"Tanaka, A., Ma, X., Takahashi, A. & Vierling, J. M. Primary biliary cholangitis. Lancet 404, 1053\u20131066 (2024).","journal-title":"Lancet"},{"key":"82854_CR12","doi-asserted-by":"publisher","first-page":"423","DOI":"10.4254\/wjh.v12.i8.423","volume":"12","author":"RT Yokoda","year":"2020","unstructured":"Yokoda, R. T., & Rodriguez, E. A.Review: Pathogenesis of cholestatic liver diseases. World J. Hepatol. 12, 423\u2013435 (2020).","journal-title":"World J. Hepatol."},{"key":"82854_CR13","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.jhep.2020.02.012","volume":"72","author":"MH Harms","year":"2020","unstructured":"Harms, M. H., van Buuren, H. R. & van der Meer, A. J. Reply to: \u2018Switching vs. add-on strategy in PBC treatment: Lessons from UDCA and bezafibrate experience\u2019. J. Hepatol. 72, 1211\u20131212 (2020).","journal-title":"J. Hepatol."},{"key":"82854_CR14","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1136\/gutjnl-2019-319057","volume":"69","author":"MH Harms","year":"2020","unstructured":"Harms, M. H. et al. Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut 69, 1502\u20131509 (2020).","journal-title":"Gut"},{"key":"82854_CR15","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","volume":"55","author":"C Corpechot","year":"2011","unstructured":"Corpechot, C., Chazouill\u00e8res, O. & Poupon, R. Early primary biliary cirrhosis: Biochemical response to treatment and prediction of long-term outcome. J. Hepatol. 55, 1361\u20131367 (2011).","journal-title":"J. Hepatol."},{"key":"82854_CR16","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1111\/apt.12522","volume":"38","author":"V Papastergiou","year":"2013","unstructured":"Papastergiou, V. et al. Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: Results from a 29-year cohort study. Aliment. Pharmacol. Ther. 38, 1354\u20131364 (2013).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"82854_CR17","doi-asserted-by":"publisher","first-page":"609187","DOI":"10.3389\/fonc.2021.609187","volume":"11","author":"B Li","year":"2021","unstructured":"Li, B. et al. Nomogram for the prediction of high-grade dysplasia and invasive carcinoma in patients with intraductal papillary Mucinous neoplasms of the pancreas based on variables of noninvasive examination. Front. Oncol. 11, 609187 (2021).","journal-title":"Front. Oncol."},{"key":"82854_CR18","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1111\/jvh.12160","volume":"21","author":"H Liu","year":"2014","unstructured":"Liu, H. et al. Neutrophil-lymphocyte ratio: A novel predictor for short-term prognosis in acute-on-chronic hepatitis B liver failure. J. Viral Hepat. 21, 499\u2013507 (2014).","journal-title":"J. Viral Hepat."},{"key":"82854_CR19","doi-asserted-by":"publisher","first-page":"e015304","DOI":"10.1136\/bmjopen-2016-015304","volume":"7","author":"L Lin","year":"2017","unstructured":"Lin, L. et al. Does neutrophil-to-lymphocyte ratio predict 1-year mortality in patients with primary biliary cholangitis? Results from a retrospective study with validation cohort. BMJ Open. 7, e015304 (2017).","journal-title":"BMJ Open."},{"key":"82854_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.5009\/gnl18271","volume":"12","author":"JJ Yoo","year":"2018","unstructured":"Yoo, J. J. et al. Prognostic value of biochemical response models for primary biliary cholangitis and the additional role of the neutrophil-to-lymphocyte ratio. Gut Liver. 12, 714\u2013721 (2018).","journal-title":"Gut Liver"},{"key":"82854_CR21","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cgh.2024.01.039","volume":"22","author":"L Zheng","year":"2024","unstructured":"Zheng, L. et al. Hypercholesterolemia is associated with dysregulation of lipid metabolism and poor prognosis in primary biliary cholangitis. Clin. Gastroenterol. Hepatol. 22, 1265\u20131274e19 (2024).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"82854_CR22","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1186\/s12876-021-01974-4","volume":"21","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y. et al. The liver steatosis severity and lipid characteristics in primary biliary cholangitis. BMC Gastroenterol. 21, 395 (2021).","journal-title":"BMC Gastroenterol."},{"key":"82854_CR23","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.stemcr.2020.12.008","volume":"16","author":"H Hayashi","year":"2021","unstructured":"Hayashi, H. et al. Modeling human bile acid transport and synthesis in stem cell-derived hepatocytes with a patient-specific mutation. Stem Cell. Rep. 16, 309\u2013323 (2021).","journal-title":"Stem Cell. Rep."},{"key":"82854_CR24","doi-asserted-by":"publisher","first-page":"154173","DOI":"10.1016\/j.phymed.2022.154173","volume":"102","author":"J Liu","year":"2022","unstructured":"Liu, J. et al. Oleanolic acid alleviates ANIT-induced cholestatic liver injury by activating Fxr and Nrf2 pathways to ameliorate disordered bile acids homeostasis. Phytomedicine 102, 154173 (2022).","journal-title":"Phytomedicine"},{"key":"82854_CR25","doi-asserted-by":"publisher","first-page":"3046","DOI":"10.3390\/biomedicines10123046","volume":"10","author":"VI Reshetnyak","year":"2022","unstructured":"Reshetnyak, V. I. & Maev, I. V. Features of lipid metabolism disorders in primary biliary cholangitis. Biomedicines 10, 3046 (2022).","journal-title":"Biomedicines"},{"key":"82854_CR26","unstructured":"Low-dose atorvastatin. Improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. https:\/\/pubmed.ncbi.nlm.nih.gov\/19782361\/"},{"key":"82854_CR27","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s11883-004-0104-8","volume":"6","author":"S Fazio","year":"2004","unstructured":"Fazio, S. & Linton, M. F. The role of fibrates in managing hyperlipidemia: Mechanisms of action and clinical efficacy. Curr. Atheroscler Rep. 6, 148\u2013157 (2004).","journal-title":"Curr. Atheroscler Rep."},{"key":"82854_CR28","unstructured":"Placebo-Controlled, A. Trial of Bezafibrate in primary biliary cholangitis. https:\/\/pubmed.ncbi.nlm.nih.gov\/29874528\/"},{"key":"82854_CR29","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","volume":"21","author":"C Levy","year":"2023","unstructured":"Levy, C., Manns, M. & Hirschfield, G. New treatment paradigms in primary biliary cholangitis. Clin. Gastroenterol. Hepatol. 21, 2076\u20132087 (2023).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"82854_CR30","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/hep.30552","volume":"70","author":"A Honda","year":"2019","unstructured":"Honda, A. et al. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology 70, 2035\u20132046 (2019).","journal-title":"Hepatology"},{"key":"82854_CR31","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1007\/s00535-014-0998-z","volume":"50","author":"A Tanaka","year":"2015","unstructured":"Tanaka, A., Hirohara, J., Nakanuma, Y., Tsubouchi, H. & Takikawa, H. Biochemical responses to bezafibrate improve long-term outcome in asymptomatic patients with primary biliary cirrhosis refractory to UDCA. J. Gastroenterol. 50, 675\u2013682 (2015).","journal-title":"J. Gastroenterol."},{"key":"82854_CR32","unstructured":"Improving prognosis in primary biliary cholangitis\u2014Therapeutic options and strategy. https:\/\/pubmed.ncbi.nlm.nih.gov\/30343714\/"},{"key":"82854_CR33","first-page":"63","volume":"111","author":"J Mart\u00ednez","year":"2019","unstructured":"Mart\u00ednez, J., Aguilera, L. & Albillos, A. Risk stratification and treatment of primary biliary cholangitis. Rev. Esp. Enferm Dig. 111, 63\u201370 (2019).","journal-title":"Rev. Esp. Enferm Dig."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82854-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82854-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T22:04:04Z","timestamp":1735423444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-82854-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["82854"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-82854-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"30 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The present study protocol was approved by the Ethics Committee of the Second Affiliated Hospital of Kunming Medical University. The requirement for informed consent was waived by Ethics Committee of the Second Affiliated Hospital of Kunming Medical University (YJ-2023-96) due to retrospective nature of study. The first people\u2019s hospital of Yunnan Province ethics committee also approved this retrospective study and waived patient informed consent (KHLL2023-KY160).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}}],"article-number":"31369"}}